NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-06571
Issuer: Merck & Co., Inc.
Exchange: NEW YORK STOCK EXCHANGE LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 2000 Galloping Hill Road
Kenilworth,
NEW JERSEY
07033
Telephone number: (908) 740-4000
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
1.125% Notes due 2021
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
o 17 CFR 240.12d2-2(a)(1)
x 17 CFR 240.12d2-2(a)(2)
o 17 CFR 240.12d2-2(a)(3)
o 17 CFR 240.12d2-2(a)(4)
o  Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
o  Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements for the Securities Exchange Act of 1934, NEW YORK STOCK EXCHANGE LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2021-10-15ByLauren FrawleyRegulation Analyst
Date NameTitle
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Mar 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Merck Charts.

Merck & Co., Inc. News

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Thursday 28 March 2024 (1 day ago) • Business Wire
GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News
Wednesday 27 March 2024 (2 days ago) • IH Market News
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Wednesday 27 March 2024 (3 days ago) • Business Wire
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Thursday 21 March 2024 (1 week ago) • Business Wire
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Wednesday 20 March 2024 (1 week ago) • Business Wire
FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
Saturday 16 March 2024 (2 weeks ago) • PR Newswire (US)
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Friday 15 March 2024 (2 weeks ago) • Business Wire
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Wednesday 13 March 2024 (2 weeks ago) • Business Wire
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Monday 11 March 2024 (3 weeks ago) • Business Wire
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Thursday 7 March 2024 (3 weeks ago) • Business Wire
Futures Pointing To Continued Weakness On Wall Street
Wednesday 6 March 2024 (3 weeks ago) • IH Market News
Merck to Participate in the Barclays 26th Annual Global Healthcare Conference
Tuesday 5 March 2024 (3 weeks ago) • Business Wire

More Merck & Co., Inc. News Articles